Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
Research ArticleConference Proceedings

PDA Biosimilars Workshop Report (September 27—28, 2018)—Getting It Right the First Time for Biosimilar Marketing Applications

Stephan Krause, Emanuela Lacana, Joel Welch, Marjorie Shapiro, Christopher Downey, Jee Chung, Qing Zhou, Martijn Van Der Plas, Chantal Depatie, Bev Ingram, Catherine Srebalus-Barnes, Alla Polozova, Barbara Rellahan, Daeseok Choi, Richard Burdick, Thomas Stangler and Emily Shacter
PDA Journal of Pharmaceutical Science and Technology July 2019, 73 (4) 401-416; DOI: https://doi.org/10.5731/pdajpst.2019.010215
Stephan Krause
1AstraZeneca Biologics, 1 Medimmune Way, Gaithersburg, MD 20878;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Stephan.Krause@astrazeneca.com
Emanuela Lacana
2CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Welch
2CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marjorie Shapiro
2CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Downey
2CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jee Chung
2CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qing Zhou
2CDER, U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, Silver Spring, MD 20993;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martijn Van Der Plas
3Medicines Evaluation Board (MEB), Graadt van Roggenweg 500, 3531 AH Utrecht, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chantal Depatie
4Health Canada, 100 Eglantine Driveway, Ottawa, ON K1A 0K9, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bev Ingram
5Pfizer Inc., 1 Burtt Road, Andover, MA 01810;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Srebalus-Barnes
6Pfizer Inc., 275 North Field Drive, Lake Forest, IL 60045;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alla Polozova
7Amgen Inc., 360 Binney Street, Cambridge, MA 02142;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Rellahan
8Amgen, Inc., 601 13th Street, NW, Suite 1100 North, Washington, DC 20005;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daeseok Choi
9CELLTRION Inc., 19, Academy-ro 51, Yeonsu-gu, Incheon 406-840, Republic of Korea;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Burdick
10Burdick Statistical Consulting, LLC, 7783 Renegade Hill Drive, Colorado Springs, CO 80923;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Stangler
11Novartis, Biochemiestraße 10, 6336 Langkampfen, Austria; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Shacter
12ThinkFDA, LLC, 710 Erie Ave, Takoma Park, MD 20912
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
Loading

References

  1. 1.
    Health Canada Guidance Document: Information and submission requirements for biosimilar biologic drugs, December 2016. https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/information-submission-requirements-biosimilar-biologic-drugs.html.
  2. 2.
    FDA Guidance for Industry: Data Integrity and Compliance with Drug CGMP, December 2018.
  3. 3.
    US Code of Federal Regulations, Title 21, Part 11.
PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology: 73 (4)
PDA Journal of Pharmaceutical Science and Technology
Vol. 73, Issue 4
July/August 2019
  • Table of Contents
  • Index by Author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PDA Biosimilars Workshop Report (September 27—28, 2018)—Getting It Right the First Time for Biosimilar Marketing Applications
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
PDA Biosimilars Workshop Report (September 27—28, 2018)—Getting It Right the First Time for Biosimilar Marketing Applications
Stephan Krause, Emanuela Lacana, Joel Welch, Marjorie Shapiro, Christopher Downey, Jee Chung, Qing Zhou, Martijn Van Der Plas, Chantal Depatie, Bev Ingram, Catherine Srebalus-Barnes, Alla Polozova, Barbara Rellahan, Daeseok Choi, Richard Burdick, Thomas Stangler, Emily Shacter
PDA Journal of Pharmaceutical Science and Technology Jul 2019, 73 (4) 401-416; DOI: 10.5731/pdajpst.2019.010215

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PDA Biosimilars Workshop Report (September 27—28, 2018)—Getting It Right the First Time for Biosimilar Marketing Applications
Stephan Krause, Emanuela Lacana, Joel Welch, Marjorie Shapiro, Christopher Downey, Jee Chung, Qing Zhou, Martijn Van Der Plas, Chantal Depatie, Bev Ingram, Catherine Srebalus-Barnes, Alla Polozova, Barbara Rellahan, Daeseok Choi, Richard Burdick, Thomas Stangler, Emily Shacter
PDA Journal of Pharmaceutical Science and Technology Jul 2019, 73 (4) 401-416; DOI: 10.5731/pdajpst.2019.010215
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • P1: Regulatory Perspective on Biosimilar Marketing Applications
    • Regulatory Perspective on Biosimilar Marketing Applications
    • Evolving EU Views on Analytical Similarity
    • A Reviewer's Perspective of Biosimilar Submissions
    • P1: Summary of Concurrent Breakout Roundtable Discussions
    • P1: Panel Discussion
    • The Trapeze and the Trap Door: Navigating High-Level Technical Challenges in Biosimilar Development
    • Data Quality Considerations for Biosimilar Development
    • Key Lessons Learned from Navigating the Challenges Associated with Biosimilar Product Development
    • A Systematic Approach to Establish a Manufacturing Control Strategy in Biosimilar Development: A Regulatory Perspective
    • P2: Summary of Panel Question and Answer Session
    • P2: Summary of Concurrent Breakout Roundtable Discussions
    • P2: Panel Discussion
    • Moderator: Joel T. Welch, PhD, Review Chief, CDER, FDA
    • P2: Summary of Concurrent Breakout Sessions
    • P3: Demonstrating Analytical Similarity: The Role of Statistical Tools
    • Reflections on Comparability (Similarity) and Methodology
    • Statistical Tools for Demonstrating Analytical Similarity: Range Test, Equivalence Test of Means, and Distribution Comparisons
    • Performance Characteristics of Commonly Used Statistical Approaches in the Evaluation of Analytical Similarity
    • P3: Summary of Panel Question and Answer Session
    • P3: Summary of Concurrent Breakout Roundtable Discussions
    • P3: Panel Discussion
    • Conflict of Interest Declaration
    • Abbreviations
    • References
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Proceedings of the 2023 Viral Clearance Symposium, Session 2: Viral Clearance Strategy and Case Studies
  • Proceedings of the 2023 Viral Clearance Symposium, Session 5: Viral Clearance Strategy and Process Understanding
  • Proceedings of the 2023 Viral Clearance Symposium, Session 8: Cell Banks, Advanced Technologies (ATMPs, NGS)
Show more Conference Proceedings

Similar Articles

Keywords

  • Viral clearance
  • Viral safety
  • Viral Clearance Symposium
  • Upstream processing
  • Downstream processing
  • Resin lifetime
  • Facility risk mitigation
  • Submission
  • Strategy
  • Regulatory agencies
  • Health Canada
  • FDA
  • PEI
  • Regulatory perspective
  • Novel format molecules
  • Continuous processing

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2025 PDA Journal of Pharmaceutical Science and Technology Print ISSN: 1079-7440  Digital ISSN: 1948-2124

Powered by HighWire